ROS1 G2101A

CI-VAR-00001669Explore in graph →NP_002935.2:p.Gly2101AlaNM_002944.2:c.6302G>CCIViC 518

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
ROS1 G2101A AND CD74::ROS1 Fusion	Crizotinib	Predictive	D	Supports Resistance	2	accepted	EID1259 Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib. PMID 25688157 · Song et al., 2015 · Open in CIViC	civic
ROS1 G2101A AND CD74::ROS1 Fusion	Foretinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID1260 Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib. PMID 25688157 · Song et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.